Blood Grouping Reagents, Anti-Fya, Anti-Jka, Anti-Jkb, Anti-S, Anti-s, Anti-K, Anti-P1
The FDA has provided approval information for several monoclonal Blood Grouping Reagents, including Anti-Fya, Anti-Jka, Anti-Jkb, Anti-S, Anti-s, Anti-K, and Anti-P1. These products are designated as Rare Antisera for Column Agglutination Technology (RASCAT).
Manufacturers of monoclonal blood grouping reagents, immunohematology laboratories, and clinical facilities utilizing the Ortho ID-Micro Typing System.
This approval formalizes the use of specific rare monoclonal antisera within a proprietary column agglutination platform. It suggests a continued regulatory shift or expansion toward standardized automated or semi-automated typing systems for rare blood group antigens. Regulatory teams should note the specific manufacturing designation (RASCAT) and the platform-dependent nature of these approvals, which likely necessitates strict adherence to matched-system validation.
QA/RA teams should ensure technical files and labeling for these monoclonal reagents specifically reference compatibility with the Ortho ID-Micro Typing System. Laboratory managers should verify that internal protocols for these 'Rare Antisera' align with the validated column agglutination technology platform specified in the approval.
Products approval information are designated as Rare Antisera for Column Agglutination Technology (RASCAT) Monoclonal Blood Grouping Reagents (BGRs) and are manufactured for use with the Ortho ID-Micro Typing System™.
Open in openFDA / FDA.gov